JRJohanne Pereira Ribeiro

Johanne Pereira Ribeiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johanne Pereira Ribeiro has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of psychotherapy on narrative identity: a systematic review protocol

    by Johanne Pereira Ribeiro, Emma Helena Thuesen, Majse Lind

    Objective: This systematic review aims to investigate the effect of psychotherapy compared to standard treatment or no treatment on the narrative identity domains; autobiographical reasoning, structural aspects and motivational/affective themes in individuals aged 13 years and older. Introduction: Narrative identity refers to the evolving life story individuals construct to understand themselves and their development over time. Disruptions in narrative identity have been documented across a range of psychiatric disorders and are associated with poorer psychological functioning. Although individual studies suggest that psychotherapy may promote more adaptive narrative identities, no systematic review has attempted to synthesize the evidence regarding effects of psychotherapy on narrative identity characteristics. Eligibility criteria: The review will include randomized controlled trials and non-randomized comparative intervention studies involving participants aged ≥13 years, with or without psychopathology. Eligible studies must evaluate manualized psychotherapeutic interventions and include a comparison condition. Studies without a comparator, uncontrolled pre–post designs, case series, and non-psychotherapeutic interventions will be excluded.Methods: PsycINFO, Embase (Ovid), MEDLINE (Ovid), and Web of Science will be searched from inception without language or publication year restrictions. Gray literature sources, including dissertations and preprint repositories, will also be searched. Two reviewers will independently conduct study selection, critical appraisal, and data extraction. Risk of bias will be assessed using design-specific tools. Random-effects meta-analyses will be conducted where appropriate; otherwise, findings will be synthesized narratively.Review registration: PROSPERO CRD420261301465

  • Methylphenidate denied access to WHO’s list of essential medicines for the third time

    by Ole Jakob Storebø, Henriette Edemann-Callesen, Johanne Pereira Ribeiro, Sophie Juul, Sabrina Katja Nestved, Helene Speyer, Andreas Hoff, Charlotte Lunde, Christian Gluud

  • Open Access

    Treatment Moderators of Symptom Severity in Psychotherapy for People with Borderline Personality Disorder: Systematic Review with Meta-Analyses of Individual Participant Data

    by Johanne Pereira Ribeiro, Jutta Stoffers-Winterling, Mie Sedoc Jørgensen, Sophie Juul, Minoo Matbouriahi, David Fisher, Wouter van Ballegooijen, Mickey T. Kongerslev, Erik Simonsen, Eirini Karyotaki, et al.

    Introduction: Borderline personality disorder (BPD) is a complex and heterogeneous condition. Psychotherapy reduces symptom severity; however, characteristics of the individual may influence treatment outcomes. This systematic review examined whether specific baseline variables moderate the effect of psychotherapy on BPD severity through individual participant data meta-analysis (IPD-MA). Methods: A literature search up to 12 May 2025 across 10 databases (including PubMed, Medline, Embase, PsycINFO, CINAHL, Web of Science, and Cochrane CENTRAL) identified randomised clinical trials (RCTs) comparing psychotherapy to treatment as usual (TAU) or clinical management control interventions (CM) for BPD. Authors of included trials were contacted to retrieve IPD. IPD-MAs employed a one-stage random-effects approach to estimate treatment effects and potential moderators in bivariate linear mixed-effects models. The study was registered with PROSPERO (CRD42021210688). Results: Out of 33,696 records identified, 42 RCTs (3,848 participants) were eligible. IPD was obtained from 19 trials (1,482 participants). All trials had an overall high risk of bias or some concerns regarding risk of bias. There was a high rate of missing data across trials (378/1,482, 25.1%). IPD-MA showed that psychotherapy significantly reduced BPD severity compared to TAU/CM (β: −0.25, 95% CI: −0.43 to −0.07, SE: 0.09, p = 0.0065; 19 trials, 1,104 participants). Significant negative moderators were co-occurring depressive disorder(s) (β: 0.31, 95% CI: 0.03 to 0.59) and exposure to sexual trauma (β: 0.60, 95% CI: 0.16 to 1.04), while positive moderators were co-occurring anxiety disorder(s) (β: −0.34, 95% CI: −0.64 to −0.03) and alcohol use disorder(s) (AUD) (β: −0.34, 95% CI: −0.67 to −0.01). Conclusion: Psychotherapy may be especially beneficial for BPD with co-occurring anxiety. Patients with co-occurring AUD should not be excluded from treatment; rather, treatment motivation should be emphasised. Further, clinicians should prioritise trauma-informed care.


  • Open Access

    Short-term versus long-term psychotherapy for borderline personality disorder: a protocol for an individual patient data pooled analysis of two randomised clinical trials

    by Sophie Juul, Shelley McMain, Markus Harboe Olsen, Alexander Chapman, Johanne Pereira Ribeiro, Ole Jakob Storebø, Janice Kuo, Emilie Hestbaek, Caroline Barkholt Kamp, Marie Rishede, et al.

    Background The evidence for the optimal duration of psychotherapy for borderline personality disorder (BPD) is scarce. Two previous trials have compared different durations of psychotherapy. The first compared 6 months versus 12 months of dialectical behaviour therapy for BPD (the FASTER trial). The second compared 5 months versus 14 months of mentalisation-based therapy for BPD (the MBT-RCT trial). The primary objective of the present study will be to provide an individual patient data pooled analysis of two randomised clinical trials by combining the two short-term groups and the two long-term groups from the FASTER and MBT-RCT trials, thereby providing greater statistical power than the individual trials. Accordingly, we will evaluate the overall evidence on the effects of short-term versus long-term psychotherapy for BPD and investigate whether certain subgroups might benefit from short-term versus long-term psychotherapy. Methods An individual patient data pooled analysis of the FASTER trial and the MBT-RCT trial will be conducted. The primary outcome will be a composite of the proportion of participants with a suicide, a suicide attempt or a psychiatric hospitalisation. The secondary outcome will be the proportion of participants with self-harm. Exploratory outcomes will be BPD symptoms, symptom distress, level of functioning and quality of life. We will primarily assess outcomes at 15 months after randomisation for the FASTER trial and at 16 months after randomisation for the MBT-RCT trial. Predefined subgroups based on the design variables in the original trials will be tested for interaction with the intervention as follows: trial, sex (male compared with female), age (below or at 30 years compared with above 30 years) and baseline level of functioning (Global Assessment of Functioning baseline score at 0–49 compared with 50–100). Ethics and dissemination The statistical analyses will be performed on anonymised trial data that have already been approved by the respective ethical committees that originally assessed the included trials. The final analysis will be published in a peer-reviewed scientific journal and the results will be presented at national seminars and international conferences. PROSPERO registration number CRD42024612840.

  • Open Access

    Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses

    by Johanne Pereira Ribeiro, Sophie Juul, Mickey T. Kongerslev, Mie Sedoc Jørgensen, Birgit A Völlm, Henriette Edemann-Callesen, Christian Sales, Julie P. Schaug, Klaus Lieb, Erik Simonsen, et al.

    Background: Medications are commonly used to treat co-occurring psychopathology in persons with borderline personality disorder (BPD)Aims: To systematically review and integrate the evidence of medications for treatment of co-occurring psychopathology in people with BPD, and explore the role of comorbidities.Method: Building on the current Cochrane review of medications in BPD, an update literature search was done in March 2024. We followed the methods of this Cochrane review, but scrutinised all identified placebo-controlled trials post hoc for reporting of non BPD-specific (‘co-occurring’) psychopathology, and explored treatment effects in subgroups of samples with and without defined co-occurring disorders. GRADE ratings were done to assess the evidence certainty.Results: Twenty-two trials were available for quantitative analyses. For antipsychotics, we found very-low-certainty evidence (VLCE) of an effect on depressive symptoms (standardised mean difference (SMD) −0.22, P = 0.04), and low-certainty evidence (LCE) of an effect on psychotic–dissociative symptoms (SMD −0.28, P = 0.007). There was evidence of effects of anticonvulsants on depressive (SMD −0.44, P = 0.02; LCE) and anxious symptoms (SMD −1.11, P < 0.00001; VLCE). For antidepressants, no significant findings were observed (VLCE). Exploratory subgroup analyses indicated a greater effect of antipsychotics in samples including participants with co-occurring substance use disorders on psychotic–dissociative symptoms (P = 0.001).Conclusions: Our findings, based on VLCE and LCE only, do not support the use of pharmacological interventions in people with BPD to target co-occurring psychopathology. Overall, the current evidence does not support differential treatment effects in persons with versus without defined comorbidities. Medications should be used cautiously to target co-occurring psychopathology.


  • Open Access

    Major mistakes or errors in the use of trial sequential analysis in systematic reviews or meta-analyses – the METSA systematic review

    by Christian Gunge Riberholt, Markus Harboe Olsen, Joachim Birch Milan, Sigurlaug Hanna Hafliðadóttir, Jeppe Houmann Svanholm, Elisabeth Buck Pedersen, Charles Chin Han Lew, Mark Aninakwah Asante, Johanne Pereira Ribeiro, Vibeke Wagner, et al.

    Background: Systematic reviews and data synthesis of randomised clinical trials play a crucial role in clinical practice, research, and health policy. Trial sequential analysis can be used in systematic reviews to control type I and type II errors, but methodological errors including lack of protocols and transparency are cause for concern. We assessed the reporting of trial sequential analysis. Methods: We searched Medline and the Cochrane Database of Systematic Reviews from 1 January 2018 to 31 December 2021 for systematic reviews and meta-analysis reports that include a trial sequential analysis. Only studies with at least two randomised clinical trials analysed in a forest plot and a trial sequential analysis were included. Two independent investigators assessed the studies. We evaluated protocolisation, reporting, and interpretation of the analyses, including their effect on any GRADE evaluation of imprecision. Results: We included 270 systematic reviews and 274 meta-analysis reports and extracted data from 624 trial sequential analyses. Only 134/270 (50%) systematic reviews planned the trial sequential analysis in the protocol. For analyses on dichotomous outcomes, the proportion of events in the control group was missing in 181/439 (41%), relative risk reduction in 105/439 (24%), alpha in 30/439 (7%), beta in 128/439 (29%), and heterogeneity in 232/439 (53%). For analyses on continuous outcomes, the minimally relevant difference was missing in 125/185 (68%), variance (or standard deviation) in 144/185 (78%), alpha in 23/185 (12%), beta in 63/185 (34%), and heterogeneity in 105/185 (57%). Graphical illustration of the trial sequential analysis was present in 93% of the analyses, however, the Z-curve was wrongly displayed in 135/624 (22%) and 227/624 (36%) did not include futility boundaries. The overall transparency of all 624 analyses was very poor in 236 (38%) and poor in 173 (28%). Conclusions: The majority of trial sequential analyses are not transparent when preparing or presenting the required parameters, partly due to missing or poorly conducted protocols. This hampers interpretation, reproducibility, and validity. Study registration: PROSPERO CRD42021273811


  • Open Access

    Perspectives on Dialectical Behavior Therapy and Mentalization-Based Therapy for Borderline Personality Disorder: Same, Different, Complementary?

    by Jutta M Stoffers-Winterling, Ole Jakob Storebø, Erik Simonsen, Mie Sedoc Jørgensen, Johanne Pereira Ribeiro, Mickey T Kongerslev, Klaus Lieb

    Current evidence suggests that individuals with borderline personality disorder (BPD) are likely to benefit from specialized, or BPD-specific, treatments. Dialectical behavior therapy (DBT) and mentalization-based treatment (MBT) are currently the most intensively researched BPD treatments. Reviewing the current research, this paper highlights similarities and differences between the two treatments, and discusses possible ways they could complement each other. As the effectiveness of specialized treatments for BPD in general has been determined with some certainty, research now tends towards individualized approaches, identifying predictors of optimal treatment response. However, it is still to be settled who might profit from a combination of or sequential treatment with DBT and MBT.


  • Methylphenidate denied access to the WHO List of Essential Medicines for the second time

    by Johanne Pereira Ribeiro, Charlotte Lunde, Christian Gluud, Erik Simonsen, Ole Jakob Storebø

    Essential medicines are those that satisfy the priority healthcare needs of the majority of the population and, as such, should be available in a functioning healthcare system at all times. This concerns the availability of appropriate dosages, amounts and quality. The costs of an essential medicine should be set at a level, which is affordable to the individual in a given community. To ensure low costs, sufficient supply and rational use of essential medicines, the World Health Organization (WHO) created the first Model List of Essential Drugs in 1977 (now Model List of Essential Medicines). The list has since then been updated 22 times, most recently in September 2021.4 The selection of a medication as an essential medicine should be based on its relevancy to disease patterns, the quality and cost-effectiveness of the medicine, its pharmacokinetics and acceptability, notwithstanding the evidence of its performance in a variety of settings as well as evidence of its efficacy and safety.5


  • Comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis”

    by Johanne Pereira Ribeiro, Mie Sedoc Jørgensen, Ole Jakob Storebø